Lilly CEO Dave Ricks in Wednesday’s third-quarter earnings call acknowledged that the company is at the mercy of wholesaler ...

Despite disappointing third-quarter results for Regeneron’s high-dose Eylea injection, analysts continued to be cautiously ...

While an FDA advisory committee saw signals of efficacy for Lexicon Pharmaceuticals’ sotagliflozin, the panel of external ...

Bristol Myers Squibb’s third-quarter results benefited from sales of its legacy brands Eliquis and Revlimid, as well as ...

In another delay for the psychedelic treatment space, Compass Pathways announced adjusted timelines for two Phase III trials ...

Wednesday’s update to the regulator’s drug shortage database is good news for Novo Nordisk, which has struggled to keep up ...

The biotech beat Wall Street’s third-quarter revenue forecast by 6%, driven by increased uptake of its achondroplasia drug ...

AbbVie’s Humira missed Wall Street’s expectations in the third quarter but Skyrizi and Rinvoq’s continuing outperformance ...

Following disappointing results for an antibiotic candidate whose development program is now being suspended, Spero ...

Biogen touted strong Q3 sales of its Alzheimer’s drug Leqembi a day after announcing a deal worth up to $1.45 billion with ...

While Amgen’s third-quarter financial results on Wednesday were “somewhat uneventful,” investors continue to be focused on ...

Approved by the FDA in July to treat adults with early symptomatic Alzheimer’s disease, Eli Lilly’s Kisunla reduced the brain ...